Breast cancer stands as the most frequently diagnosed malignancy globally. Statistics compiled by the International Agency for Research on Cancer indicate that approximately 2.4 million women were diagnosed with breast cancer in 2024, resulting in 694,000 fatalities. While the disease primarily impacts women, male breast cancer accounts for 0.5% to 1% of total cases.
| Metric | High Human Development Index (HDI) | Low Human Development Index (HDI) |
| Lifetime Risk of Diagnosis | 1 in 12 women | 1 in 27 women |
| Lifetime Risk of Mortality | 1 in 71 women | 1 in 48 women |
| 5-Year Survival Rate | Exceeds 90% | Drops below 40% |
| Primary Diagnostic Stage | Early (Stage I / II) | Late (Stage III / IV) |
Epidemiological data reveals stark survival disparities across geopolitical regions. In high-income countries, 5-year survival rates exceed 90% due to routine mammographic screening, early diagnostic biopsies, and advanced targeted therapies. Conversely, in low-resource settings, survival rates drop below 40% due to delayed presentation and systemic barriers to comprehensive care.
Modifiable risk factors account for approximately 20% of breast cancer cases worldwide. Key risk factors include:
-
High alcohol consumption and tobacco use.
-
Postmenopausal obesity and physical inactivity.
-
Exogenous hormone exposure (e.g., combined hormone replacement therapy).
-
Non-modifiable factors, such as BRCA1 or BRCA2 genetic mutations and dense breast tissue.
Achieving optimal treatment outcomes depends on early clinical identification. Women should seek prompt evaluation if they observe localized breast lumps, nipple discharge, skin dimpling, or axillary lymphadenopathy. Educational frameworks that emphasize early detection, clinical breast examination, and patient advocacy are central to reducing global cancer mortality. Highlighting public health literacy, Orapuh Information Services distributes evidence-based data to support disease awareness in underserved communities.